Amneal Pharmaceuticals Inc (NASDAQ: AMRX) kicked off on Tuesday, up 0.77% from the previous trading day, before settling in for the closing price of $7.79. Over the past 52 weeks, AMRX has traded in a range of $5.01-$9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 7.85%. While this was happening, its average annual earnings per share was recorded -4.30%. With a float of $126.70 million, this company’s outstanding shares have now reached $309.77 million.
Let’s determine the extent of company efficiency that accounts for 7850 employees. In terms of profitability, gross margin is 35.34%, operating margin of 7.0%, and the pretax margin is -4.59%.
Amneal Pharmaceuticals Inc (AMRX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Amneal Pharmaceuticals Inc is 59.11%, while institutional ownership is 41.90%. The most recent insider transaction that took place on Nov 22 ’24, was worth 142,946. In this transaction Director of this company sold 17,058 shares at a rate of $8.38, taking the stock ownership to the 267,175 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Director sold 33,229 for $8.34, making the entire transaction worth $277,130. This insider now owns 53,402 shares in total.
Amneal Pharmaceuticals Inc (AMRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -4.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.00% during the next five years compared to -23.74% drop over the previous five years of trading.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Take a look at Amneal Pharmaceuticals Inc’s (AMRX) current performance indicators. Last quarter, stock had a quick ratio of 0.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.91. Likewise, its price to free cash flow for the trailing twelve months is 24.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.68, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
Looking closely at Amneal Pharmaceuticals Inc (NASDAQ: AMRX), its last 5-days average volume was 1.01 million, which is a drop from its year-to-date volume of 1.37 million. As of the previous 9 days, the stock’s Stochastic %D was 36.69%. Additionally, its Average True Range was 0.28.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 45.38%, which indicates a significant increase from 21.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.46% in the past 14 days, which was lower than the 37.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.39, while its 200-day Moving Average is $7.41. However, in the short run, Amneal Pharmaceuticals Inc’s stock first resistance to watch stands at $7.90. Second resistance stands at $7.94. The third major resistance level sits at $8.04. If the price goes on to break the first support level at $7.76, it is likely to go to the next support level at $7.66. Should the price break the second support level, the third support level stands at $7.62.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
The company with the Market Capitalisation of 2.43 billion has total of 309,844K Shares Outstanding. Its annual sales at the moment are 2,394 M in contrast with the sum of -83,990 K annual income. Company’s last quarter sales were recorded 702,470 K and last quarter income was -160 K.
